Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Alison Balfour"'
Publikováno v:
Pediatric Investigation, Vol 6, Iss 3, Pp 163-170 (2022)
ABSTRACT Importance Staphylococcus lugdunensis (S. lugdunensis) is a coagulase‐negative staphylococcus (CoNS), found commonly as skin flora in humans. While most species of CoNS are clinically benign, S. lugdunensis can exhibit a similar virulence
Externí odkaz:
https://doaj.org/article/5a0c53137d954d4eb349b914b54dadff
Autor:
Craig L. Leonardi, Lena Lemke, Sohaib Hachaichi, Alison Balfour, Julia Jauch-Lembach, Norman Gaylis, Ines Brueckmann, Teodora Festini, Andrew Blauvelt, Piotr Wiland
Publikováno v:
Biodrugs
Background SDZ-ADL (GP2017; Sandoz GmbH, Austria) is an EMA-/FDA-approved adalimumab biosimilar. The effect of SDZ-ADL on quality of life (QoL) and patient-reported outcomes (PROs) was assessed as part of two phase III studies, one in patients with m
Autor:
Julia Jauch-Lembach, Oliver von Richter, Andrej Skerjanec, Halimuniyazi Haliduola, Alison Balfour, Lena Lemke, Britta Zehnpfennig
Publikováno v:
Expert Opinion on Biological Therapy. 19:1057-1064
Introduction: Antidrug antibody (ADA) development is known to occur with adalimumab treatment and impacts adalimumab exposure. Here, we compare the impact of immunogenicity on pharmacokinetics (PK) across two randomized PK studies of GP2017, an appro
Autor:
Piotr Wiland, O. von Richter, Lena Lemke, Andrew Blauvelt, Alison Balfour, F. Furlan, Norman Gaylis
Publikováno v:
Annals of the Rheumatic Diseases. 80:1130-1131
Background:Adalimumab (ADL) is typically self-administered every 2 weeks (W) as a subcutaneous (s.c.) injection by patients (pts) for diverse indications, including rheumatoid arthritis (RA), psoriatic arthritis (PsA), and psoriasis (PsO). Conflictin
Autor:
Shou-Shan Chiang, Masaki Nagasawa, Takashi Akiba, Jin-Bor Chen, J. Mark Hexham, Seiichi Obayashi, Hung-Chun Chen, Guido Junge, Masafumi Fukagawa, Alison Balfour
Publikováno v:
Nephrology. 16:743-750
Aim: SBR759 is a calcium-free, polymeric, iron(III)-based oral phosphate binder, in development for the treatment of hyperphosphatemia. The efficacy and safety of SBR759 was compared with sevelamer hydrochloride in chronic kidney dialysis patients on
Autor:
Naomi Schlesinger, Eduardo Mysler, Gerhard Krammer, Hsiao-Yi Lin, Udayasankar Arulmani, Alison Balfour, Alexander So, Peter Sallstig, Marc De Meulemeester, Jozef Rovensky
Publikováno v:
Annals Rheumatic Diseases
Annals of the Rheumatic Diseases, vol. 70, no. 7, pp. 1264-1271
Annals of the Rheumatic Diseases
Annals of the Rheumatic Diseases, vol. 70, no. 7, pp. 1264-1271
Annals of the Rheumatic Diseases
Objective This study assessed the efficacy and safety of canakinumab, a fully human anti-interleukin 1 beta monoclonal antibody, for prophylaxis against acute gouty arthritis flares in patients initiating urate-lowering treatment.Methods In this doub
Autor:
Julia Jauch-Lembach, Alison Balfour, Joseph F. Fowler, Jean-Phillippe Lacour, Craig L. Leonardi, Andrew Blauvelt, Ellen Schuck
Publikováno v:
American Journal of Gastroenterology. 112:S419
Autor:
Jin-Bor, Chen, Shou-Shan, Chiang, Hung-Chun, Chen, Seiichi, Obayashi, Masaki, Nagasawa, J Mark, Hexham, Alison, Balfour, Guido, Junge, Takashi, Akiba, Masafumi, Fukagawa
Publikováno v:
Nephrology (Carlton, Vic.). 16(8)
SBR759 is a calcium-free, polymeric, iron(III)-based oral phosphate binder, in development for the treatment of hyperphosphatemia. The efficacy and safety of SBR759 was compared with sevelamer hydrochloride in chronic kidney dialysis patients on hemo